Protalix BioTherapeutics Announces Research Project For Inflammatory Bowel Disease (IBD)

Protalix BioTherapeutics Announces Research Project For Inflammatory Bowel Disease (IBD)
Protalix Bio Therapeutics recently announced an update on the development of a new oral anti-TNF (PRX-106) for Inflammatory Bowel Disease (IBD). Protalix is a bio-pharmaceutical company highly focused on and committed to developing and commercializing recombinant proteins with therapeutic potential through its own system of plant cell-based expression, the ProCellEx. The company’s technique is an exquisite way

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *